PMVP · PMV Pharmaceuticals, Inc.
$1.06
-0.04 (-3.64%)
At close · Jul 29
Market Cap
$57.06M
Shares
53.33M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.10
Open$1.17
Day$1.10–1.17
52W$1.02–1.88
Avg vol 30d312K
Short int2.4M · 4.5% float · 6.3d
Short vol76%
Last earningsMay 27, 2025
DataSep 2020–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−15%
below
Price vs 50-day avg
−10%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
9%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−15%
trailing
6-month return
+2%
trailing
YTD return
−12%
this year
Relative strength
−6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
2 of 69 funds reported for Jun 30 · net -30.8K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.54% of float · ▼ -16.9% MoM · 6.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
69 holders — mid 3-yr range
Squeeze score
47
elevated · 0–100
Fundamentals
EPS growth
−30%
Y/Y
Free cash flow
$-73.6M
Balance sheet
$38.0M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
7.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−15%
Bearish
Price vs 50-day avg
−10%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
9%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
2 of 69 funds reported for Jun 30 · net -30.8K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.54% of float · ▼ -16.9% MoM · 6.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
69 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 9%
52-wk high $2
vs 200-day avg -15%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and marketable securities | $93.5M | first quarter 2026 | — |
| Median duration of response | 8.2 | first quarter 2026 | — |
| Median time to response | 1.3 | first quarter 2026 | — |
| Net cash used in operations | $19.7M | three months ended March 31, 2026 | — |
| Overall response rate (ORR) per investigator assessment | 44% | first quarter 2026 | — |
| Overall response rate (ORR) post data cutoff | 46% | post March 29, 2026 data cutoff | — |
| Overall response rate (ORR) | 34% | PYNNACLE Phase 2 data as of September 4, 2025 data cut-off | — |
| Overall response rate (ORR) - ovarian cancer cohort | 46% | PYNNACLE Phase 2 data as of September 4, 2025 data cut-off | — |
| Overall response rate (ORR) - ovarian cancer cohort (post September 4, 2025 data cut-off) | 50% | After the September 4, 2025 data cut-off | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PMVP
this stock
PMV Pharmaceuticals, Inc.
|
$57.06M | -12.0% | — | — | 4.5% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PMVP | -16.0% | -14.7% | +1.9% | -17.9% | -12.0% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -15.0% | -14.7% | -5.6% | -17.1% | -20.6% |